Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pirfenidone
Drug ID BADD_D01783
Description Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.
Indications and Usage For the treatment of idiopathic pulmonary fibrosis (IPF).
Marketing Status approved; investigational
ATC Code L04AX05
DrugBank ID DB04951
KEGG ID D01583
MeSH ID C093844
PubChem ID 40632
TTD Drug ID D02WCI
NDC Product Code 0480-3610; 60862-005; 69766-030; 76072-1006; 42385-924; 69539-120; 42385-923; 42385-925; 42571-336; 69097-940; 72205-182; 0781-8085; 0480-3611; 65372-1197; 82920-705; 16729-468; 46708-479; 69238-1640; 62332-480; 0781-2158; 62207-004; 31722-872; 50228-442; 69539-119; 57297-140; 73309-052; 46708-480; 69097-988; 69238-1641; 42571-329; 46016-5312; 31722-873; 72205-181; 76282-716; 0781-8086; 53104-7712; 69037-0013; 60219-1640; 60219-1641; 47621-311; 59285-013; 59651-199; 50228-443; 50242-121; 60219-1642; 62332-479; 46016-5310; 16729-467; 42385-926; 42571-335; 50228-441; 50242-122; 69097-987; 76282-715; 76282-717; 11014-0214; 46438-0648; 62512-0070; 50242-123
UNII D7NLD2JX7U
Synonyms pirfenidone | 5-methyl-1-phenyl-2-(1H)-pyridone | Esbriet | deupirfenidone | 1-phenyl-5-(trideuteriomethyl)-1,2-dihydropyridin-2-one | Deskar
Chemical Information
Molecular Formula C12H11NO
CAS Registry Number 53179-13-8
SMILES CC1=CN(C(=O)C=C1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary arterial hypertension22.06.01.002; 24.08.03.0030.001206%-
Orthostatic hypertension17.05.01.018; 24.08.02.0100.000241%-
Aortic arteriosclerosis24.04.01.004---
Liver injury09.01.07.022; 12.01.17.0120.000723%-
Regurgitation07.01.07.0040.000530%-
Oropharyngeal pain07.05.05.004; 22.12.03.0160.004774%
Upper-airway cough syndrome22.12.03.0360.000844%
Faeces soft07.01.03.0080.000530%-
Irregular breathing22.02.01.0260.000844%-
Anal incontinence07.01.06.029; 17.05.01.0210.000362%
Abnormal loss of weight14.03.02.0190.000651%-
Chronic respiratory failure14.01.04.005; 22.02.06.0050.001085%-
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.000723%-
Hemiplegic migraine17.14.02.004; 24.03.05.0120.000241%-
Jaw cyst15.02.04.035; 16.11.03.0020.000362%-
Lung adenocarcinoma16.19.01.002; 22.08.01.0070.000482%-
Lung carcinoma cell type unspecified stage IV16.19.02.006; 22.08.01.0190.000362%-
Lymphadenopathy mediastinal01.09.01.025; 22.09.03.0060.000241%-
Throat cancer16.19.02.007; 22.08.02.0080.000241%-
Restrictive pulmonary disease22.01.02.0250.000844%-
Terminal state08.01.03.0790.000362%-
Pulmonary artery dilatation22.06.03.0050.000723%-
Sarcopenia15.05.06.0040.000241%-
Pulmonary pain22.12.01.0100.000362%-
End stage renal disease20.01.03.0190.000241%-
Disease complication08.01.03.0870.000603%-
Hepatic cytolysis09.01.07.0360.000241%-
Illness08.01.03.0910.003448%-
Lung diffusion disorder22.02.07.0220.000482%-
Lung opacity22.12.01.0060.000362%-
The 11th Page    First    Pre   11 12    Next   Last    Total 12 Pages